BioVie Inc.

NasdaqCM:BIVI Stock Report

Market Cap: US$43.8m

BioVie Management

Management criteria checks 4/4

BioVie's CEO is Cuong Viet Do, appointed in Apr 2021, has a tenure of 3.75 years. total yearly compensation is $777.08K, comprised of 79.5% salary and 20.5% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $114.65K. The average tenure of the management team and the board of directors is 3.6 years and 6.5 years respectively.

Key information

Cuong Viet Do

Chief executive officer

US$777.1k

Total compensation

CEO salary percentage79.5%
CEO tenure3.8yrs
CEO ownership0.3%
Management average tenure3.6yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

Oct 14

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

Sep 06

BioVie: Four Potential Catalysts Around The Corner

Jun 07

CEO Compensation Analysis

How has Cuong Viet Do's remuneration changed compared to BioVie's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$27m

Jun 30 2024US$777kUS$618k

-US$33m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$43m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023US$2mUS$618k

-US$50m

Mar 31 2023n/an/a

-US$49m

Dec 31 2022n/an/a

-US$41m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022US$5mUS$300k

-US$26m

Mar 31 2022n/an/a

-US$150m

Dec 31 2021n/an/a

-US$145m

Sep 30 2021n/an/a

-US$143m

Jun 30 2021US$2mn/a

-US$184m

Compensation vs Market: Cuong Viet's total compensation ($USD777.08K) is about average for companies of similar size in the US market ($USD641.95K).

Compensation vs Earnings: Cuong Viet's compensation has been consistent with company performance over the past year.

CEO

Cuong Viet Do (58 yo)

3.8yrs

Tenure

US$777,082

Compensation

Mr. Cuong Viet Do, M.B.A, is Independent Director of Adagene Inc. from November 2022. He serves as the Founder and Chairman at M6P Therapeutics. Mr. Do serves as a Director at Seneca Therapeutics, Inc., si...

Leadership Team

NamePositionTenureCompensationOwnership
Cuong Viet Do
President3.8yrsUS$777.08k0.26%
$ 114.6k
Joanne Kim
CFO, Treasurer & Corporate Secretary6.3yrsUS$339.25k0.044%
$ 19.1k
Joseph Palumbo
Executive VP of R&D and Chief Medical Officer3.2yrsUS$669.58k0.057%
$ 25.2k
Clarence Ahlem
Senior Vice President of Operations1.2yrsno datano data
Penelope Markham
Senior Vice President of Liver Disease Programno datano datano data
Denise Smith
Senior Vice President of Manufacturing & Development6yrsno datano data
Christopher Reading
Senior Vice President of Alzheimer's Disease Program3.5yrsno datano data

3.6yrs

Average Tenure

66.5yo

Average Age

Experienced Management: BIVI's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cuong Viet Do
President8.7yrsUS$777.08k0.26%
$ 114.6k
Richard Jay Berman
Independent Director5.6yrsUS$156.01k0.029%
$ 12.7k
Sigmund Rogich
Independent Director4.6yrsUS$127.19k0.018%
$ 7.8k
Robert Hariri
Independent Director4.6yrsUS$127.19k0.037%
$ 16.3k
James Lang
Independent Chairman8.1yrsUS$171.11k0.051%
$ 22.4k
Michael Sherman
Independent Director7.5yrsUS$164.24k0.024%
$ 10.4k

6.5yrs

Average Tenure

65yo

Average Age

Experienced Board: BIVI's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 11:01
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioVie Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Charles DuncanCantor Fitzgerald & Co.
Jay OlsonOppenheimer & Co. Inc.